Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
CTXR closed up 1.4 percent on Friday, January 19, 2018, on 63 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||N/A||Down||Up|
|See historical CTXR trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 19||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Jan 19||Doji - Bearish?||Reversal||0.00%|
|Jan 19||Stochastic Reached Overbought||Strength||0.00%|
|Jan 19||Weak + Overbought||Other||0.00%|
|Jan 19||Wide Bands||Range Expansion||0.00%|
|Jan 19||Weak, Overbought and Reversal Signs||Reversal||0.00%|
|Jan 19||Overbought Stochastic||Strength||0.00%|
|Jan 19||Up 3 Days in a Row||Strength||0.00%|
|Jan 19||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 18||NR7||Range Contraction||1.40%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CTXR news...
|52 Week High||5.49|
|52 Week Low||2.56|
|200-Day Moving Average||0.0|
|50-Day Moving Average||4.4577|
|20-Day Moving Average||4.077|
|10-Day Moving Average||4.047|
|Average True Range||0.3595|
|Chandelier Exit (Long, 3 ATRs )||3.7415|
|Chandelier Exit (Short, 3 ATRs )||4.5485|
|Upper Bollinger Band||4.3835|
|Lower Bollinger Band||3.7705|
|Percent B (%b)||0.93|
|MACD Signal Line||-0.1063|
|Market Cap||35.81 Million|
|Num Shares||8.25 Million|
|Price-to-Earnings (P/E) Ratio||-2.19|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||4.70|
|Resistance 3 (R3)||4.70||4.57||4.64|
|Resistance 2 (R2)||4.57||4.48||4.58||4.62|
|Resistance 1 (R1)||4.46||4.43||4.52||4.46||4.60|
|Support 1 (S1)||4.22||4.24||4.28||4.22||4.08|
|Support 2 (S2)||4.09||4.19||4.10||4.06|
|Support 3 (S3)||3.98||4.09||4.04|
|Support 4 (S4)||3.98|